Morphic Holding (Morphic Holding) FCF Margin % : 0.00% (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Morphic Holding FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Morphic Holding's Free Cash Flow for the three months ended in Dec. 2023 was $-28.67 Mil. Morphic Holding's Revenue for the three months ended in Dec. 2023 was $0.00 Mil. Therefore, Morphic Holding's FCF Margin % for the quarter that ended in Dec. 2023 was 0.00%.

As of today, Morphic Holding's current FCF Yield % is -8.11%.

The historical rank and industry rank for Morphic Holding's FCF Margin % or its related term are showing as below:

MORF' s FCF Margin % Range Over the Past 10 Years
Min: -21795.2 Med: -200.59 Max: 2253.66
Current: -21795.2

During the past 7 years, the highest FCF Margin % of Morphic Holding was 2253.66%. The lowest was -21795.20%. And the median was -200.59%.

MORF's FCF Margin % is ranked worse than
94.37% of 1031 companies
in the Biotechnology industry
Industry Median: -148.24 vs MORF: -21795.20

Morphic Holding FCF Margin % Historical Data

The historical data trend for Morphic Holding's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Morphic Holding FCF Margin % Chart

Morphic Holding Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-258.05

-103.54

-426.80

-143.12

-21,795.20

Morphic Holding Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-410.46	-6,142.80	-	-	-

Competitive Comparison of Morphic Holding's FCF Margin %

For the Biotechnology subindustry, Morphic Holding's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Morphic Holding's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Morphic Holding's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Morphic Holding's FCF Margin % falls into.

Morphic Holding FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Morphic Holding's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-113.553	/	0.521
	=	-21,795.20 %

Morphic Holding's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-28.667	/	0
	=	%

Morphic Holding FCF Margin % Related Terms

Thank you for viewing the detailed overview of Morphic Holding's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Morphic Holding (Morphic Holding) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Morphic Holding Inc (NAS:MORF) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

31Y:Germany 31Y:Germany

Address

35 Gatehouse Drive, A2, Waltham, MA, USA, 02451

Website

http://www.morphictx.com

Morphic Holding Inc is a biopharmaceutical company applying its insights into integrins to discover and develop a pipeline of oral small-molecule integrin therapeutics. Integrins are a target class with multiple approved injectable blockbuster drugs for the treatment of serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis, and cancer.

Executives

William Devaul	officer: General Counsel and Secretary	C/O MORPHIC HOLDING, INC., 35 GATEHOUSE DRIVE, A2, WALTHAM MA 02451
Bruce Rogers	officer: Chief Scientific Officer	C/O MORPHIC HOLDING, INC., 35 GATEHOUSE DRIVE, A2, WALTHAM MA 02451
Marc Schegerin	officer: CFO and COO	ARQULE INC, 1 WALL ST FL6, BURLINGTON MA 01803
Praveen P. Tipirneni	director, officer: President and CEO	C/O MORPHIC HOLDING, INC.,, 35 GATEHOUSE DRIVE, A2, WALTHAM MA 02451
Farrell Robert E Jr	officer: VP Finance and Ops, Secretary	CAMBRIDGE DISCOVERY PARK, 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140
Joseph P Slattery	director	C/O TRANSENTERIX, INC., 635 DAVIS DRIVE, SUITE 300, MORRISVILLE NC 27560
Martin Edwards	director	15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803
Timothy A Springer	director, 10 percent owner	36 WOODMAN ROAD, CHESTNUT HILL MA 02467
Peter Linde	officer: Chief Medical Officer	C/O MORPHIC HOLDING, INC., 35 GATEHOUSE DRIVE A2, WALTHAM ME 02451
Nisha Nanda	director	281 TRESSER BOULEVARD, STAMFORD CT 06901
Amir Nashat	director	10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121
Omega Fund V Gp, L.p.	director	888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Susannah Gray	director	10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA 92121
Vikas Goyal	director	C/O SR ONE, LTD., 161 WASHINGTON ST., SUITE 500, EIGHT TOWER BRIDGE, CONSHOHOCKEN PA 19428
Otello Stampacchia	director	888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199